Plain-English translation of NCT06043011 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
RUBIN is a long-term tracking study for people with certain blood cancers, including chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Waldenström's macroglobulinemia. Researchers will collect information about your medical history, treatments you receive (chosen by your doctor), and how the treatment affects you over time. The study aims to understand what treatments work best in real-world practice and how they impact patients' daily lives.
Doctors want to better understand how different blood cancer treatments perform outside of controlled research settings and which approaches help patients live better, longer lives. This study will identify gaps in current care and areas where treatment could be improved.
You likely qualify if…
You likely don't qualify if…
You will be enrolled when you begin or have recently begun treatment for your blood cancer. Your doctor will collect information about your diagnosis, past treatments, and medical history at the start. Throughout your care, the study will track all treatments you receive, how you respond, and any side effects. For the first year, you may also answer questions about how your health affects your daily life and well-being. You won't need to do anything extra beyond your regular doctor visits—the study simply documents the care you're already receiving.
AI-generated summary from trial data · Jul 22, 2026 · Not medical advice
Germany
Sponsor
iOMEDICO AG
Enrollment target
~2,950 participants
Started
September 2023
Primary completion
December 2033
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Martina Jänicke, Dr.
Universitätsklinikum Augsburg, Germany
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.